• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    What's new in HPB oncology: what does the oncologist need from the histopathologist?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lamarca, Angela
    Affiliation
    The Christie Hospital, Manchester
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Oncology care for patients with advanced hepato-pancreato-biliary (HPB) cancer is rapidly evolving. Newest data is supporting the role of Precision Medicine strategies in patients diagnosed with advanced cholangiocarcinoma. In addition to tumour-agnostic targets such as NTRK fusions or MMR de?ciency tumour, there are new targets speci?c to cholangiocarcinoma, such as FGFR2 fusions (present in around 15-20% of intrahepatic cholangiocarcinoma) and IDH-1 mutations (present in around 15/20% of intrahepatic cholangiocarcinoma). Currently, molecular pro?ling is available as part of clinical trials and the above-mentioned treatment strategies do require adequate molecular pro?ling for suitable patients to be identi?ed and to be allocated to these new treatment options. Unfortunately, 1 in every 4 biopsy samples that are sent for molecular pro?ling fail such analysis, with majority failing due to poor quantity of tumour tissue present in the block sent for analysis. We therefore need close collaboration between histopathologist and oncologist at time of selecting best block available for molecular pro?ling so we avoid samples with no tumour being sent for analysis with the subsequent waiting time lost for patients with very poor prognosis for whom delay on treatment could be harmful. Should no suitable tissue be available for analysis, early re-biopsy could also be considered to increase changes of successful molecular pro?ling.
    Citation
    Lamarca A. What's New in HPB Oncology: What Does the Oncologist Need From the Histopathologist? Journal of Pathology. 2021;255:S8-S.
    Journal
    Journal of Pathology
    URI
    http://hdl.handle.net/10541/624693
    Type
    Other
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.